KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Interest Expenses (2016 - 2026)

Emergent BioSolutions has reported Interest Expenses over the past 16 years, most recently at $11.0 million for Q1 2026.

  • For Q1 2026, Interest Expenses fell 25.17% year-over-year to $11.0 million; the TTM value through Mar 2026 reached $55.6 million, down 9.45%, while the annual FY2025 figure was $59.3 million, 16.48% down from the prior year.
  • Interest Expenses for Q1 2026 was $11.0 million at Emergent BioSolutions, down from $14.7 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $28.6 million in Q2 2023 and troughed at $7.8 million in Q2 2022.
  • A 5-year average of $15.7 million and a median of $14.7 million in 2025 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: surged 266.67% in 2023 and later crashed 57.87% in 2024.
  • Year by year, Interest Expenses stood at $12.8 million in 2022, then soared by 69.53% to $21.7 million in 2023, then plummeted by 31.8% to $14.8 million in 2024, then dropped by 0.68% to $14.7 million in 2025, then decreased by 25.17% to $11.0 million in 2026.
  • Business Quant data shows Interest Expenses for EBS at $11.0 million in Q1 2026, $14.7 million in Q4 2025, and $15.2 million in Q3 2025.